Health & Biotech
PharmAust patients successfully complete first dosing level for Motor Neurone Disease trial
Health & Biotech
Check Up: Moderna posts crazy cancer vaccine results, says melanoma recurrence down by almost half
Health & Biotech
ASX Health Stocks: Cannabis play ECS Botanics enters burgeoning German market, share price up 20pc
Health & Biotech
ASX Health Stocks: Mach7 lands biggest customer in history, share prices surges 20pc
Health & Biotech
ASX Tech & Biotech: Kleos launches new geospatial intelligence product, Radiopharm scores FDA approval
Health & Biotech
ScoPo’s Powerplays: Health sector rattled but ASX X-ray stocks dance, led by boss PME up 28% since June
Health & Biotech
Weed Week: Budding Asian pot market could be flying at US$120m by 2026
Health & Biotech
Medlab Clinical looks to dual list on the NASDAQ in the new year
Health & Biotech
ASX Tech & Biotech: Island Pharma files investigational application for new Dengue Fever drug
Health & Biotech
Xmas comes early for Nutritional Growth Solutions as US sales accelerate after giant Walmart deal
Health & Biotech
PharmAust is preparing for a successful Phase 2 completion
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall this week and in need of a good rest after a tough 2022
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.